← Back to Search

NA

Colonoscopy Screening for Colorectal Cancer Risk in IBD

N/A
Recruiting
Research Sponsored by Ottawa Hospital Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights

Study Summary

This trial will compare strategies for colorectal neoplasia screening in people with IBD, to see if one is better at finding cancerous lesions. 1952 participants needed.

Who is the study for?
This trial is for adults over 18 with Inflammatory Bowel Disease (IBD) who are in symptomatic remission and have had IBD for at least 8 years, or any duration if they also have primary sclerosing cholangitis. They should be undergoing colorectal cancer screening with a high-definition colonoscopy but can't join if they've had major colon surgery, recent neoplasia diagnosis, poor bowel prep quality, incomplete colonoscopy, significant inflammation or a history of colorectal cancer.Check my eligibility
What is being tested?
The study compares two strategies during high-definition white light colonoscopies: one where only visible lesions are sampled versus the conventional method that samples both visible lesions and normal-appearing mucosa. The goal is to see which strategy is better at detecting neoplasia without being worse than the other. A total of 1952 participants will be enrolled to determine this.See study design
What are the potential side effects?
While not explicitly stated here, standard side effects from a colonoscopy may include abdominal pain or discomfort, bloating, gas cramps and potential risk of bleeding or perforation from biopsy procedures.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of persons with ≥ 1 neoplastic lesion detected
Secondary outcome measures
CRC incidence over five years following study colonoscopy (obtained through patient linkage to provincial cancer registries five years following trial completion)
Mean # high grade dysplastic lesions or colorectal cancers per person
Mean # tissue samples per person
+6 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Experimental: Intervention GroupExperimental Treatment1 Intervention
Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy targeted biopsies (biopsies of any pre-cancerous lesions observed by the doctor) and/or removal of any polyps will be undertaken.
Group II: Control GroupActive Control1 Intervention
Participants will undergo standard colonoscopy as part of their routine IBD surveillance. During this colonoscopy both random (approximately 32 to 40) and targeted biopsies (and/or removal of any polyps) will be undertaken.

Find a Location

Who is running the clinical trial?

Ottawa Hospital Research InstituteLead Sponsor
561 Previous Clinical Trials
2,783,742 Total Patients Enrolled

Media Library

Standard colonoscopy with targeted biopsies (NA) Clinical Trial Eligibility Overview. Trial Name: NCT05809999 — N/A
Inflammatory Bowel Disease Research Study Groups: Experimental: Intervention Group, Control Group
Inflammatory Bowel Disease Clinical Trial 2023: Standard colonoscopy with targeted biopsies Highlights & Side Effects. Trial Name: NCT05809999 — N/A
Standard colonoscopy with targeted biopsies (NA) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05809999 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor accepting individuals older than thirty-five?

"This medical trial is searching for eligible participants who are within the age range of 18 to 100 years old."

Answered by AI

Am I qualified to partake in this investigation?

"1952 participants with inflammatory bowel disease are needed for this research. Eligible individuals must be between 18 and 100 years of age to qualify."

Answered by AI

What is the maximum enrollment capacity of this clinical trial?

"Yes, according to the information found on clinicaltrials.gov this trial is currently enrolling participants with recruitment commencing on September 23rd 2022 and last updated March 30th 2023. This medical experiment requires 1952 volunteers across 11 different sites."

Answered by AI

Are there still vacancies within this investigation?

"Affirmative. According to clinicaltrials.gov, this examination is in the process of seeking volunteers. The trial was first posted on September 23rd 2022 and was most recently refreshed on March 30th 2023; it aims to enroll 1952 subjects at 11 different sites."

Answered by AI

Could you please outline the number of healthcare facilities that are currently administering this trial?

"Currently, there are 11 sites recruiting for this trial including St. Paul's Hospital in Vancouver, University of Manitoba, Health Sciences Centre in Winnipeg and Eastern Regional Health Authority in St. John's as well as a handful of other medical centres."

Answered by AI

Who else is applying?

What site did they apply to?
Ottawa Hospital Research Institute
Mount Sinai Hospital
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

I need the money.
PatientReceived no prior treatments
~1001 spots leftby Dec 2025